Remuneration in Danish Large Cap Companies Benchmarking of Remuneration of Executive Management and Boards 2013 - 2016 Remuneration in Danish Large Cap Companies

Total Page:16

File Type:pdf, Size:1020Kb

Remuneration in Danish Large Cap Companies Benchmarking of Remuneration of Executive Management and Boards 2013 - 2016 Remuneration in Danish Large Cap Companies Remuneration in Danish Large Cap companies Benchmarking of remuneration of executive management and boards 2013 - 2016 Remuneration in Danish Large Cap companies Content Introduction 3 Key takeaways 4 Current trends 5 Experience from the UK 8 Overview 9 Methodology 10 Remuneration of executive directors 11 Base salary 15 Pension 18 Bonus (STIs) 19 Long-Term Incentives (LTIs) 22 Board remuneration 31 How can Deloitte help? 32 Our contacts 33 Appendix 35 2 Remuneration in Danish Large Cap companies Introduction This report gives an overview of and insight into reported with the required level of detail to be included remuneration of executive directors and boards of listed in our analysis. All the included company reports companies within the Danish Large Cap1 index. In March in accordance with IFRS and financial reporting on 2017 the Large Cap Index is comprised of 38 companies, remuneration of executives are more specifically of which the names can be found in a list in the appendix. governed by IFRS 2 and the Danish Financial Statements These companies represent some of the largest Danish Act. Remuneration of executive directors is required by companies from a wide range of industries, from financial IFRS to be disclosed on both fixed and variable elements services to energy and supplies. for executive management. Although reporting this level of detail for all individual members of management is During 2016 no companies left the Danish Large Cap not a requirement, it is however best practice guidance Index, while DFDS, NKT Holding, SimCorp and Össur from the Committee on Corporate Governance3. LTI entered following OMX Nasdaq’s annual review in programmes must also be disclosed separately in their December 2015. The annual review of the Large Cap entirety, which includes all participants, both executives Index in December 2016 resulted in an expansion of the and non-executives. Where applicable, we have index by ALK-Abelló, Ambu, Jeudan, Schouw & Co., and compared our findings with previous studies performed Spar Nord. During 2016 Scandinavian Tobacco Group on the Danish market to put recent developments into a (February), DONG Energy (June) and Nets (September) long-term perspective. also entered the index through their IPOs. Disclaimer Out of the companies of the Large Cap Index, 35 This report is aimed at giving an overview of executive companies have financial year-ends 31 December 2016, remuneration and the use of LTI in Danish Large while 3 companies have financial year-ends either 31 cap companies. There may be very good reasons August or 30 September. The annual reports have been for a particular company to lie inside and outside of published during or before March 2017. One company, benchmarked ranges. This could be due to differences G4S2, had not published its annual report for 2016 at in company size, industry, market volatility or other the time of the writing of this report and has hence been company-specific factors. When using the report we omitted from the 2016 benchmarks. Hence, this report is recommend that you consult your advisers on the based on the data from 37 companies. interpretation of the data and its relevance to your particular circumstances. The analysis is based strictly on publicly available information obtained from annual reports, company This report does not constitute the provision of advice websites, press releases, general assembly notes, or service to any reader of this report, and hence remuneration policies, etc. Not all companies report Deloitte may not be named in a company’s public their remuneration with the same level of detail. For documentation as having provided material assistance to all the analysed benchmarks, we report the number the remuneration committee based solely on the use of of companies for which the required data has been the information provided in this report. 1. Nasdaq OMX Copenhagen Large Cap Index. The index is comprised of 41 share listings of which 3 are listings of multiple share classes (38 individual companies). Nasdaq OMX Copenhagen Large Cap includes Danish listed companies with a market cap of above EUR 1bn 2. G4S Plc is incorporated in the UK and is dually listed on both London and Copenhagen Stock Exchanges. G4S Plc reports under UK regulation and is more naturally compared to other UK-based listed companies. 3. https://corporategovernance.dk/recommendations-corporate-governance 3 Remuneration in Danish Large Cap companies Key takeaways Variable versus fixed remuneration Median base salaries for CEOs and CFOs of executive directors increased are DKK 8.2m and DKK 4.8m. between 2013 and 2016 so that variable remuneration now comprises 37% compared to previously 31%. Short-term incentives (STI or bonus) are approx. 40% of base salary for executive CEOs receive a higher degree of variable directors. remuneration compared to CFOs and Other Executive Directors. Around two thirds of long-term incentives (LTI) programmes comprise performance Base salaries of executive directors have share units or restricted stock units. increased significantly during the last 4 years. CEO base salaries have increased by approx. 10% annually while CFO base The average size of outstanding LTI salaries have only increased by 2%. programmes is approx. 1.5% of the share capital. Companies allocate approx. 0.1% of the share capital in yearly allocations, The increase in CFO base salaries has indicating that the size of LTI programmes been affected by the many replacements has decreased on earlier years. of CFOs. Adjusted for this turnover, the increase in base salaries for the remaining CFOs has been approx. 8% annually or LTI allocations increased for CEOs while around the same level as for CEOs. Nine it decreased for CFOs from 2013 to 2016. CFOs were replaced between 2014 and There is a sign that boards in general wish 2016. for their CFOs to be more risk averse (gate keepers) and that their CEOs accept more risk (innovators). 4 Remuneration in Danish Large Cap companies Current trends Danish environment The recent IPO’s of Scandinavian Tobacco Group, The Shareholder Rights Directive is an EU Dong Energy and Nets have renewed public directive, which was adopted in 2007, with the discussions about executive remuneration. purpose of setting out minimum rights and Especially the IPO of Nets and its remuneration and responsibilities for shareholders at company incentives of management drew much media and meetings held in the EU. Since the publication investor attention. During the latest months Danish there has been a number of revisions, of which institutional investors have publicly made clear that the latest is now in March 2017. long term incentives potentially are becoming too favourable for executive management. The Commission’s aim is to tackle corporate governance shortcomings relating to listed Recently the ATP stated that the incentives companies and their boards, shareholders programmes of Nets were too favourable and in (institutional investors and asset managers), future, programmes should possibly be capped in intermediaries and proxy advisors (e.g. firms order to avoid payouts to become unreasonable. In providing services to shareholders, notably recent weeks ATP have also stated that the a new voting advice) in line with long-term investment programme at Genmab which will be capped 400% of horizons. base salary, is an extreme of what they can accept as a shareholder. ATP also voiced criticism of Carlsbergs Will within the next 15 months the European proposed increases of director remuneration and Commision will issue implementation guidance, bonus at the recent annual general meeting and after which member states will have 24 months subsequently voted against the boards proposal. to bring national laws and regulation into force. We expect recent developments to have an impact on how remuneration committees (Remco) plan Individuals covered by the new voting and reporting and execute remuneration for the coming years. As regime include any member of the administrative, one direct effect, we expect that most Remco’s will management or supervisory bodies of a company. need to revisits benchmarks applied for the size and Member states can also opt to include individuals characteristics such as vesting criteria, duration, who perform similar functions. The chief executive gearing etc. We believe that communication and deputy chief executive (if applicable) are more openly on remuneration policies with key both considered directors, irrespective of their investors, such as institutional investors, will be of key membership of the board. importance in the coming years. This will be amplified with the upcoming implementation of the Shareholder The impact for Danish companies is expected to Rights Directive (see further below) and further be significant. Below we have listed some of the international alignment. key elements of the revised requirements for the remuneration policies and reporting. Shareholder Rights Directive Executive remuneration is subject to increased scrutiny in Europe. The revised Shareholder Rights Directive4 was adopted in March 2017 and may lead to significant changes across Europe. The European Commission will issue standardised guidance for the implementation of the Directive within 15 months following the adoption of the Directive. Member states will hereafter have 24 months to bring national laws/regulations into force. 4. http://www.europarl.europa.eu/sides/getDoc.do?type=TA&reference=P8-TA-2017-0067&language=EN&ring=A8-2015-0158 5 Remuneration
Recommended publications
  • Competitive Analysis & Two-Firm Comparison Paper Carlsberg Group
    Competitive Analysis & Two-Firm Comparison Paper Carlsberg Group | Sapporo Holdings Brandon Altman Professor Geraldine Wu International Studies Program: Europe Spring 2019 Word Count: 2393 – Excluding Titles 2 Table of Contents Part 1: Industry Analysis Pg. 3 Part 2: Firm Analysis Pg. 6 Part 3: Location Matters Pg. 9 References Pg. 12 ___________ Competitive Analysis & Two-Firm Comparison Paper 3 Part 1 Industry Analysis ______________________________________________________________________________ Competitive Analysis & Two-Firm Comparison Paper 4 Nature of Danish Beer Industry: The Danish beer market has proven to be an extremely attractive industry, as evidenced by the shocking increase in beer-firm numbers over the past two decades. According to Draft Mag, “at the end of the 20th century, Denmark had around a dozen breweries to its name, most conspicuously Carlsberg, one of the world’s largest brewers of industrial lager. A decade into the 21st century, the nation boasted almost 150 breweries.” This microbrewery boom brought in a large variety of craft beers that have tended to do especially well given that “the notoriously unstable Danish weather [caused] an increase in sales of craft beer due to people being driven away from the beaches and into bars or their own homes, where the consumption of craft and specialty beers is higher” (Euromonitor). On a competitive level, Denmark is a somewhat difficult market to compete in on a large scale. As stated by Euromonitor, “beer in Denmark continued to be highly consolidated with the two
    [Show full text]
  • Insights from Danish Companies Hanne Shapiro Futures and Finansforbundet Table of Contents
    SUMMARY THE FINANCIAL LABOUR MARKET OF THE FUTURE INSIGHTS FROM DANISH COMPANIES HANNE SHAPIRO FUTURES AND FINANSFORBUNDET TABLE OF CONTENTS INSIGHTS FROM DANISH COMPANIES ..................................................4 TOPIC 1 A CHANGING SECTOR –NEW PARTNERSHIPS ................................................................................................6 TOPIC 2 AUGMENTATION VS. AUTOMATION ..........................................................8 TOPIC 3 CHANGES IN HOW WE WORK ..........................................................................10 TOPIC 4 NEW ROLES FOR HR AND MANAGERS .................................................12 TOPIC 5 DEVELOPMENTS IN SKILLS ​​AND NEW JOB PROFILES ......................................................................................................14 TOPIC 6 NEW WAYS OF LEARNING ....................................................................................18 BEHIND THE RESULTS: INTERVIEWS WITH SELECT COMPANIES Hanne Shapiro Futures has conducted interviews with the following companies: Bankdata, Danske Bank, Jyske Bank, Nykredit, SimCorp, Sparekassen Kronjylland, Spar Nord Bank and Tryg Forsikring. The cases were selected based on a desire to reflect the diversification characteristic to the financial sector. However, the cases do not fully depict the diversity that characterises the financial sector and its value chain. For most of the companies, several interviews were conducted with both managers and employees. Josefine Boel Rasmussen from Finansforbundet participated
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • Aktienyt Novozymes
    Aktienyt Novozymes Hold Udfordrende markeder dæmper salgsvæksten Uændret Hold-anbefaling siden 20/04/2016 Vi fastholder vores Hold-anbefaling på Novozymes Dagens regnskab er lidt svagere, end vi havde ventet. Hård priskonkurrence i ’Bioenergi’ og økonomisk Analysedato: 10/08/2016 pressede kunder i ’Landbrug og Foder’ dæmper Novozymes’ salgsvækst. Pris- fastsættelsen af Novozymes-aktien afspejler efter vores vurdering Novozymes’ Aktuel kurs kl. 12:11: kortsigtede forretningsmuligheder. 295,00 DKK Salgsvæksten skuffer i årets 2. kvartal Omsætningen på 3.429 mio. kr. i 2. kvartal 2016 er 3,3% dårligere end vores estimat (-3,5% i Begivenhed: forhold til markedsforventningen). Resultatet af primær drift på 961 mio. kr. i 2. kvartal 2016 er 2,9% under vores estimat (-2,6% i forhold til markedsforventningen). I forhold til vores for- 2. kvartalsregnskab ventning er det specielt salget i divisionerne ’Bioenergi’ og ’Landbrug og Foder’, der viser en svagere end ventet udvikling i 2. kvartal. Novozymes justerer salgsprognosen for 2016 i lokal Seneste analyse: valuta. Selskabet venter nu en salgsvækst i lokal valuta på 2-4% i 2016 mod tidligere 3-5%. 05/08/16 – Vækst i ’Vaskemid- Novozymes forventer, at salgsvæksten i danske kroner forbliver uændret på 1-3% i 2016. ler’ – Tilbagegang i ’Bioenergi’ Salgsvæksten i ’Vaskemidler’ overgår vores forventning Den organiske salgsvækst i divisionen ’Vaskemidler’ på 4% i 2. kvartal er lidt bedre end vo- res estimat på 3%. Vi hæfter hos ved, at salget vokser i Asien drevet af øget penetration af Kalender: enzymer i flydende vaskemidler. Yderligere noterer vi os, at den positive salgsudvikling er 26/10/16 – 3.
    [Show full text]
  • Genmab Announces Data to Be Presented at 2017 ASCO Annual Meeting
    Genmab Announces Data to be Presented at 2017 ASCO Annual Meeting Media Release 8 abstracts on Genmab programs scheduled for presentation at ASCO Two daratumumab oral presentations and five daratumumab poster presentations Copenhagen, Denmark; April 20, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that seven daratumumab abstracts have been accepted for presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2 – 6. These abstracts, submitted by our collaboration partner, Janssen Biotech, Inc., include updates for the POLLUX and CASTOR trials, and the first data for a Phase I study evaluating daratumumab with carfilzomib, lenalidomide and dexamethasone in front line multiple myeloma patients, which will be presented in an oral presentation. In addition, descriptions of the Phase Ib/II study of daratumumab plus atezolizumab in non-small cell lung cancer and of our Phase I/II study with HuMax-AXL-ADC are scheduled for poster presentations at the meeting. The titles of the abstracts are currently available on the ASCO website with the full abstracts scheduled to be published on May 17, 2017. “We are very pleased that, once again, a number of abstracts based on exciting work with Genmab’s innovative therapeutic antibody products have been accepted for presentation at the prestigious ASCO conference,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. List of abstracts: Daratumumab: Efficacy Of Daratumumab In Combination with Lenalidomide Plus Dexamethasone (DRd) or
    [Show full text]
  • Annual Report 2017
    Annual Report 2017 Royal Unibrew A/S CVR no. 41 95 67 12 Contents MANAGEMENT REPORT | SIGNATURES | CONSOLIDATED FINANCIAL STATEMENTS | PARENT COMPANY FINANCIAL STATEMENTS | OTHER INFORMATION ROYAL UNIBREW ANNUAL REPORT 2017 CONTENTS MANAGEMENT REPORT 2 Contents Royal Unibrew at a Glance Corporate Social Responsibility CEO Letter: Efficient Royal Unibrew in brief 4 Corporate Social Responsibility 50 strategy execution delivers Results for 2017 and Outlook for 2018 5 continued progress Financial Highlights and Ratios 6 Management's Statement and Auditor's Report Page 7 CEO Letter: Efficient strategy execution Management's Statement on delivers continued progress 7 the Annual Report 61 Independent Auditor's Report 62 Strategy and targets Strategy 10 Consolidated Financial Statements Market outlook 11 Income Statement 66 Royal Unibrew and consumers 12 Statement of Comprehensive Income 66 Strategy Royal Unibrew and innovation 13 Balance Sheet 67 Page 9 Craft and specialty beer at Royal Unibrew 14 Cash Flow Statement 68 Terme di Crodo and LemonSoda 15 Statement of Changes in Equity 69 Royal Unibrew and efficiency 16 Contents of Notes 71 Financial targets, capital structure and distribution policy 17 Parent Company Financial Statements Outlook for 2018 18 Income Statement 102 Statement of Comprehensive Income 102 Performance Balance Sheet 103 Financial Review 21 Cash Flow Statement 104 Western Europe 25 Statement of Changes in Equity 105 Italy: Aquisition of Baltic Sea 28 Contents of Notes 107 LemonSoda Malt and Exports 31 from Gruppo Other Information Campari Governance Group Structure 119 Page 15 Shareholder Information 34 Quarterly Financial Highlights and Ratios 120 Corporate Governance 37 Definitions of Financial Highlights and Ratios 121 Risk Management 40 Disclaimer 122 Remuneration 44 Board of Directors and Executive Board 46 The Annual Report has been prepared in Danish and English.
    [Show full text]
  • Honours Programme, Industrial Track Msc Chemical and Biochemical Engineering Honours Programme in Chemical and Biochemical Engineering
    Honours Programme, Industrial Track MSc Chemical and Biochemical Engineering Honours Programme in Chemical and Biochemical Engineering In September 2009 DTU established honours programmes within the context of the regular MSc programmes (see:www.dtu.dk/ english). The programmes are open to highly qualified internation- al and Danish students. You can choose to focus your Honours Programme in Chemical and Biochemical Engineering on industrial research and development by following a special Industrial Track. Industrial Track The superb industrial contacts and the high international standing amongst the faculty of the Department have made it possible to form an industrial track within the Honours Programme. The philosophy is to enable the very best and most motivated stu- dents to gain from high-level, world-class industrial contacts in major Danish enterprises with operations all over the world. In this way we work to open new and exciting career prospects for the students within industrial research, innovation, process design, operation and management. The programme is coordinated with leading international Danish companies. Presently FLSmidth, Lundbeck, Novozymes, Haldor- Topsøe, and Hempel support the programme. Admission to Indus- trial Track is subject to acceptance by a partner company. 2 DTU Special features The Technical University of Denmark (DTU) is Scandinavia’s leading The honours programme, Industrial Track has some special features technical university and one of the top technical universities in Europe. over and above the normal MSc programme. These are: It has outstanding facilities for education and research in a large, open campus just north of Copenhagen. Masters courses are taught in Eng- Mentoring lish, in an innovative and open-minded learning environment.
    [Show full text]
  • Genmab's 2020 Capital Markets
    WELCOME Genmab’s 2020 Capital Markets Day November 13, 2020 Webcast Live from Utrecht and Princeton Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors.
    [Show full text]
  • Aktiekommentar Novozymes
    Aktiekommentar Novozymes Sælg Novozymes står på dørtærsklen til et kommercielt Uændret gennembrud i 2G-biobrændstofindustrien Aktuel kurs: 216,30 DKK Begivenhed: Vi fastholder Sælg-anbefalingen på Novozymes. Værdiansættelsen af Novozy- mes-aktien indregner efter vores vurdering allerede store forventninger til Novo- zymes’ fremtidige salg og indtjening fra 2G-biobrændstofenzymer. 2G-industrien Optakt til kapitalmar- er dog i sin spæde opstartsfase. Der er fortsat stor usikkerhed forbundet med kedsdag hvilke teknologiske løsninger, der vil blive markedsledende. Vi forventer dog, at Novozymes vil få en betydelig markedsposition som leverandør til 2G-industrien. Baggrund: Novozymes afholder kapitalmarkedsdag den 31. oktober 2013. Det overordnende tema for dagen er anden generations biobrændstof (2G) og mulighederne for Novozymes i denne indu- stri. Verdens første kommercielle 2G-bioethanolproduktion er for nylig startet op i Cresentino i Italien med Novozymes som enzymleverandør. Produktionsanlægget er opført af italienske Beta Renewables, som Novozymes ejer 10% af. Konklusion: På kapitalmarkedsdagen vil vi have fokus på følgende punkter: - Produktionsøkonomien på det italienske 2G-anlæg – er det kommercielt konkurren- cedygtigt? - Statusopdatering på Novozymes’ globale partnerskabsaftaler – tidshorisont for kom- merciel 2G-produktion på forskellige markeder - Novozymes/Beta Renewables styrker i forhold til konkurrerende teknologier Vi forventer, at Novozymes i 2015 kan opnå et globalt enzymsalg til 2G- biobrændstofsproduktion på 213 mio. kr. stigende til 2.166 mio. kr. i 2020. Vi forventer, at Ki- na og Brasilien vil agere vækstmotor for udviklingen af 2G-industrien, mens vi først forventer, at udviklingen i USA kommer op i tempo efter 2015. Det er efter vores vurdering helt centralt, at Novozymes har indgået et samarbejde med itali- enske Beta Renewables.
    [Show full text]
  • Second Pre-Clinical Milestone Met in Lundbeck Collaboration - €1 Million Milestone Payment to Genmab
    GENMAB REACHES SECOND MILESTONE IN LUNDBECK COLLABORATION - Second pre-clinical milestone met in Lundbeck collaboration - €1 million milestone payment to Genmab Copenhagen, Denmark; February 10, 2012 – Genmab A/S (OMX: GEN) announced today it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the central nervous system (CNS). The milestone triggers a payment of €1 million to Genmab. Under the collaboration with Lundbeck Genmab creates novel human antibodies to three targets identified by Lundbeck and Lundbeck has access to Genmab’s antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms. Under the terms of the agreement, Genmab received an upfront payment of €7.5 million in October 2010 (approximately DKK 56 million). Lundbeck fully funds the development of the antibodies. If all milestones in the agreement are achieved, the total value of the agreement to Genmab would be approximately €38 million (approximately DKK 283 million), plus single-digit royalties. “We are very pleased to have met the in vitro proof of concept milestone for another target in the Lundbeck collaboration. This partnership is progressing well, with this second milestone coming shortly after we achieved the first preclinical milestone in December last year,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
    [Show full text]
  • Annual Report 2020
    S I MCOR P ANNUAL REPORT 2020 SimCorp A/S • Weidekampsgade 16 • 2300 Copenhagen S • Denmark • Company reg. no: 15505281 • www.simcorp.com SIMCORP ANNUAL REPORT 2020 | 2 A leading provider of fully integrated front-to-back, multi-asset, investment management solutions to the world’s largest institutional investment management companies Empowering unmatched operational efficiency and investment enablement MANAGEMENT REPORT CONSOLIDATED FINANCIAL STATEMENTS FINANCIAL STATEMENTS OF SIMCORP A/S 3 SimCorp at a glance 17 Financial review 2020 45 Income statement 93 Income statement 4 Business units, products and clients 24 Risk management 45 Statement of comprehensive income 93 Statement of comprehensive income 5 Business unit review 27 Corporate governance report 46 Cash flow statement 94 Cash flow statement 6 Performance and highlights 31 Shareholder information 47 Statement of financial position 95 Statement of financial position 7 CEO and Chairman letter 35 Board of Directors 48 Statement of changes in equity 96 Statement of changes in equity 9 Highlights 2016-2020 38 Executive Management Board 49 Notes 97 Notes 11 Vision and strategy 39 Group Management Committee 15 Financial targets 2021 40 Statements and signatures RELATED REPORTS Sustainability Report 2020 Remuneration Report 2020 www2.simcorp.com/SustainabilityReport2020 www2.simcorp.com/RemunerationReport2020 DISCLAIMER: SimCorp’s annual report includes certain forward-looking statements regarding the Group’s future financial situation. Such statements are based on SimCorp’s current plans, estimates, and projections. By nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and are thus not a guarantee of future performance. Accordingly, the actual performance may deviate materially from that expressed in such forward-looking statements due to a variety of factors.
    [Show full text]
  • Jens Howitz (Pdf)
    Ledelsesevaluering og mangfoldighed Jens M. Howitz Managing Director Russell Reynolds Associates Januar 2014 Bestyrelsesprofil under forandring 1999 2013 Hvid, mand, midaldrende Mangfoldighed: Køn, alder, erfaring Homogen profil “Old Boys Network” Overvejende international/global Relationer og kontakter Udvælgelsesproces Dansk Kompetencedrevet Specifik baggrund og indsigt: Tidligere CEO / Generalist • Finans, SCM, Branding, CSR etc. Advokat •Emerging markeder •Brancheforståelse •Uafhængighed FTSE 100 CAC40 DAX AEX OBX OMX C20 ‘09 ‘12 ‘09 ‘12 ‘09 ’12 ‘09 ‘12 ‘09 ‘13 ’09 ’13 Female 11% 21% 8% 22% 5% 10% 14% 20% 39% 38% 10% 16% NEDs ‘Foreign’ 37% 41% 28% 31% 18% 26% 48% 53% 27% 39% 24% 35% NEDs Average Age 57 60 60 61 61 62 62 61 54 52 58 57 2 Virksomheder Novo Nordisk Lundbeck A.P.Møller – Maersk GN Store Nord Danske Bank Jyske Bank Carlsberg Topdanmark Coloplast FLSmidth & Co. Novozymes DONG Energy TDC Danish Crown Pandora Coop Danmark Vestas Wind Systems DLG Tryg Danfoss DSV Grundfos William Demant Holding LEGO Chr. Hansen Holding 3 Bestyrelsesmedlemmer 2013 vs. 2003 Anciennitet i top 25 virksomheder i DK 2013 Anciennitet i top 25 virksomheder i DK 2003 100 45 90 40 80 35 70 30 60 25 Antal Medlemmer Antal Medlemmer 50 Mænd Mænd 20 40 Kvinder Kvinder 15 30 20 10 10 5 0 0 0-3 år 3-6 år 6-9 år 9-12 år 12+ 0-3 år 3-6 år 6-9 år 9-12 år 12+ 4 Bestyrelsesmedlemmers nationalitet, top 25 2013 2003 3% 13% 6% 13% Dansk Dansk Nordisk Nordisk Andet Andet 74% 91% 5 Bestyrelsessammensætning, top 25 2013 2003 Køn: 83,9 % mænd
    [Show full text]